Literature DB >> 32386693

Pharmacologic Management of Excessive Daytime Sleepiness.

Shinichi Takenoshita1, Seiji Nishino2.   

Abstract

Excessive daytime sleepiness (EDS) is related to medical and social problems, including mental disorders, physical diseases, poor quality of life, and so forth. According to the International Classification of Sleep Disorders, Third Edition, diseases that result from EDS are narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, hypersomnia due to a medical disorder, and others. EDS is usually treated using amphetamine-like central nervous system stimulants or modafinil and its R-enantiomer, armodafinil, wake-promoting compounds unrelated to amphetamines; a variety of new drugs are under development. The side effects of some stimulants are potent and careful selection and management are required.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Excessive daytime sleepiness; Idiopathic hypersomnia; Narcolepsy; Stimulants

Year:  2020        PMID: 32386693     DOI: 10.1016/j.jsmc.2020.02.006

Source DB:  PubMed          Journal:  Sleep Med Clin        ISSN: 1556-407X


  2 in total

1.  Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.

Authors:  Stéphane Krief; Isabelle Berrebi-Bertrand; Isabelle Nagmar; Martin Giret; Simon Belliard; David Perrin; Marilyne Uguen; Philippe Robert; Jeanne-Marie Lecomte; Jean-Charles Schwartz; Olivier Finance; Xavier Ligneau
Journal:  Pharmacol Res Perspect       Date:  2021-10

2.  Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort.

Authors:  Carlotta Mutti; Valerio Brunetti; Michela Figorilli; Claudio Liguori; Fabio Pizza; Paola Proserpio; Tommaso Sacco; Giuseppe Pedrazzi; Isabelle Lecomte; Nora Blanchard; Elio Clemente Agostoni; Enrica Bonanni; Diego Centonze; Alessandro Cicolin; Giacomo Della Marca; Luigi Ferini-Strambi; Raffaele Ferri; Gian Luigi Gigli; Francesca Izzi; Rocco Liguori; Raffaele Lodi; Lino Nobili; Liborio Parrino; Fabio Placidi; Monica Puligheddu; Andrea Romigi; Maria Antonietta Savarese; Michele Terzaghi; Giuseppe Plazzi
Journal:  Neurol Sci       Date:  2022-06-25       Impact factor: 3.830

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.